Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 18;12:704112. doi: 10.3389/fphar.2021.704112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Guo, Liu, Cheng, Liu, Zheng, Liang and Xu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Metformin improves obesity and glucose metabolic disorders in DIO mice. C57BL/6J mice were treated with either metformin or drinking water as control for 4 weeks after a 12-weeks diet intervention. In DIO mice, metformin significantly reduced (A) body weight (p < 0.05), (B) fasting blood glucose (p < 0.05) but showed no remarkable effect on (C) energy intake (p > 0.05). (D) Body fat mass of DIO mice was greatly reduced by metformin (p < 0.05). (E) The Intraperitoneal glucose tolerance test and (F) intraperitoneal insulin tolerance test showed that metformin significantly improved glucose tolerance and insulin sensitivity (p < 0.05). Data are shown as mean ± SEM. *p < 0.05, HFD group vs. Chow diet group; ^# p < 0.05, HFD group vs. HFD + Metformin group; ^§ p < 0.05, HFD + Metformin vs. Chow diet group.